(Q37954205)

25 August 2017

title

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options (English)

1 reference

25 August 2017

Megan V Caram

1

1 reference

25 August 2017

Scott M Schuetze

series ordinal

2

1 reference

25 August 2017

publication date

1 December 2011

1 reference

Journal of Surgical Oncology

25 August 2017

published in

1 reference

25 August 2017

volume

104

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

888-895

1 reference

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

25 August 2017

cites work

1 reference

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.

21 January 2018

1 reference

NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

21 January 2018

1 reference

Inherited predisposition to gastrointestinal stromal tumor

21 January 2018

1 reference

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

21 January 2018

1 reference

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas

21 January 2018

1 reference

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

21 January 2018

1 reference

Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas

21 January 2018

1 reference

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

21 January 2018

1 reference

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

21 January 2018

1 reference

Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review

21 January 2018

1 reference

Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.

21 January 2018

1 reference

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

Indications for imatinib mesylate therapy and clinical management

21 January 2018

1 reference

Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec

21 January 2018

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review).

21 January 2018

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JSO.21930

1 reference

25 August 2017

1 reference